Urticaria angioedema - Symptoms, Causes, Treatment & Prevention

```html

Overview

Urticaria (commonly called hives) and angioedema are two related skin conditions that often appear together. Urticaria presents as raised, itchy wheals that change shape within minutes to hours, while angioedema involves deeper swelling of the skin or mucous membranes, especially around the eyes, lips, tongue, hands, feet, and sometimes the airway.

Both conditions are manifestations of an underlying release of histamine and other inflammatory mediators from mast cells and basophils. They can be acute (lasting < 6 weeks) or chronic (persisting > 6 weeks). When they occur together, the term **urticaria‑angioedema** is commonly used.

Who is affected? Adults of any age can develop urticaria‑angioedema, but chronic forms are most common in women (≈ 60 % of cases) and typically begin in the third to fourth decade of life. Children can also be affected, especially with acute episodes triggered by infections.

Prevalence: According to the American Academy of Dermatology, up to 20 % of the population will experience an episode of urticaria at some point in their lives. Chronic urticaria affects 0.5–1 % of adults worldwide and is a leading cause of missed work days and reduced quality of life (Mayo Clinic, 2023).

Symptoms

The clinical picture can be highly variable. Below is a comprehensive list of the most common manifestations.

Urticaria (Hives)

• Wheals – raised, pink or red plaques that are usually < 1–3 cm in diameter but can coalesce into larger patches.
• Pruritus – intense itching that may be triggered by heat, pressure, or stress.
• Fleeting nature – individual lesions typically resolve within 24 hours, although new lesions often appear elsewhere.
• Dermographism – wheals that develop after light scratching or stroking of the skin.

Angioedema

• Deep swelling of the sub‑cutaneous tissue; lesions are non‑pitting and may persist 24–72 hours.
• Facial involvement – eyelids, lips, and cheeks are most commonly affected.
• Genital and extremity swelling – can cause discomfort and limit mobility.
• Airway edema – swelling of the tongue, floor of the mouth, or larynx can cause dysphagia, voice changes, or respiratory distress (a medical emergency).
• Gastrointestinal angioedema – abdominal pain, nausea, or vomiting, especially in hereditary forms.

Associated systemic signs

• Low‑grade fever (more common with infection‑triggered acute urticaria).
• Headache or malaise.
• Rarely, joint pain or swelling if an underlying autoimmune disease is present.

Causes and Risk Factors

Urticaria‑angioedema is a symptom complex rather than a single disease. The underlying triggers can be grouped into several categories.

Allergic (IgE‑mediated) triggers

• Foods – nuts, shellfish, eggs, dairy, and certain fruits.
• Medications – antibiotics (especially penicillins), aspirin, NSAIDs, and opioids.
• Insect stings or bites.
• Latex.

Non‑allergic (non‑IgE) triggers

• Physical stimuli – cold, heat, pressure, vibration, water, or sunlight (physical urticarias).
• Infections – viral upper‑respiratory infections, Helicobacter pylori, hepatitis B/C.
• Autoimmune disorders – thyroid disease, lupus, rheumatoid arthritis; autoantibodies can activate mast cells directly.
• Stress – emotional or physical stress can exacerbate chronic urticaria.
• Hormonal changes – menstrual cycle, pregnancy, or use of oral contraceptives.

Hereditary and acquired angioedema

These are distinct from the histamine‑driven type and involve a deficiency or dysfunction of C1‑esterase inhibitor, leading to excess bradykinin. They are less common (≈ 1 per 50,000 people) but cause much more prolonged swelling and a higher risk of airway obstruction.

Risk factors

• Female sex (especially for chronic spontaneous urticaria).
• Family history of urticaria or autoimmune disease.
• Existing allergic conditions (asthma, allergic rhinitis, eczema).
• Use of ACE inhibitors or ARBs – can precipitate angioedema.

Diagnosis

Diagnosis is primarily clinical, but targeted testing helps identify triggers and rule out serious mimickers.

History and Physical Examination

• Detailed timeline of lesions, associated exposures, medication list, and any systemic symptoms.
• Physical exam to document wheal morphology, distribution, and any signs of airway involvement.

Laboratory and Skin Testing

• Complete blood count (CBC) – may reveal eosinophilia in allergic cases.
• Serum tryptase – elevated during acute mast‑cell degranulation, useful for anaphylaxis evaluation.
• Complement levels (C4, C1‑inhibitor activity) – low in hereditary or acquired angioedema.
• Autoimmune screen – antithyroid antibodies, ANA, rheumatoid factor when autoimmune disease is suspected.
• Specific IgE or skin prick testing – identifies IgE‑mediated allergens.
• Oral challenge or drug provocation test – performed in a controlled setting when medication allergy is suspected.

When to Order Imaging?

Ultrasound or CT may be needed if deep facial swelling threatens the airway, or to evaluate abdominal angioedema causing severe pain.

Treatment Options

Treatment goals are to relieve symptoms, prevent recurrences, and avoid complications.

First‑line Pharmacologic Therapy

• Second‑generation H1 antihistamines – cetirizine, loratadine, fexofenadine, or desloratadine (once daily). They cause less sedation than first‑generation agents.
• If symptoms persist after 2 weeks, increase the dose up to 4× the standard dose (off‑label) per EAACI/GA²LEN/EDF guidelines.

Second‑line Options (if antihistamines insufficient)

• H2 antihistamines (e.g., ranitidine or famotidine) added twice daily.
• Leukotriene receptor antagonists (montelukast) – helpful especially when aspirin or NSAID sensitivity coexists.
• Systemic corticosteroids – short courses (e.g., prednisone 0.5 mg/kg for ≤ 7 days) for acute flares; not recommended for long‑term control due to side‑effects.

Third‑line / Specialist‑managed Therapies

• Omalizumab (anti‑IgE monoclonal antibody) – administered subcutaneously every 2–4 weeks; effective in > 80 % of chronic spontaneous urticaria patients refractory to high‑dose antihistamines (Mayo Clinic, 2022).
• Ciclosporin – immunosuppressant reserved for severe, refractory cases; requires close monitoring of renal function and blood pressure.
• Bradykinin‑targeted agents – icatibant or berotralstat for hereditary angioedema.

Procedures

• Intramuscular epinephrine – immediate treatment for anaphylactic-type reactions or airway‑threatening angioedema.
• Airway management – intubation or cricothyrotomy in a controlled setting if breathlessness worsens.

Lifestyle & Self‑care Measures

• Avoid known triggers (e.g., specific foods, temperature extremes).
• Wear loose, breathable clothing to reduce friction‑induced dermographism.
• Keep a symptom diary to correlate flare‑ups with exposures.
• Stay well‑hydrated and maintain a balanced diet; alcohol can exacerbate hives in many patients.

Living with Urticaria‑Angioedema

Chronic disease management is a combination of medical therapy, self‑monitoring, and psychosocial support.

Daily Management Tips

• Take antihistamines at the same time each day to maintain steady blood levels.
• Carry a **self‑injectable epinephrine auto‑injector** (e.g., EpiPen) if you have a history of airway angioedema or anaphylaxis.
• Apply **cool compresses** (10‑15 min) to reduce itching and swelling – avoid ice directly on the skin.
• Use **fragrance‑free, hypoallergenic skin care products** to prevent irritant contact dermatitis.
• Engage in **stress‑reduction techniques** (mindfulness, yoga, CBT) as stress can worsen chronic urticaria.

Impact on Quality of Life

Studies show that chronic urticaria scores similarly to severe asthma in terms of disability (Cleveland Clinic, 2021). If you notice mood changes, sleep disturbances, or social withdrawal, discuss them with your clinician—psychological support or a referral to a therapist may be beneficial.

Follow‑up Schedule

• Initial follow‑up 2–4 weeks after starting or adjusting therapy.
• Quarterly visits for chronic disease until stable control is achieved.
• Prompt review if new medications are added or if symptoms suddenly worsen.

Prevention

While not all triggers can be avoided, certain strategies reduce recurrence risk.

• Identify and eliminate allergens – use testing results to guide dietary or environmental changes.
• Medication review – discuss alternatives with your prescriber if NSAIDs or ACE inhibitors precipitate episodes.
• Vaccinations – keep up‑to‑date; some infections can trigger urticaria, and vaccines are generally safe (CDC, 2023).
• Skin protection – use sunscreen for photosensitive urticaria and avoid extreme temperature changes.
• Weight management – obesity is a risk factor for chronic urticaria; a balanced diet and regular exercise can help.

Complications

Most cases are benign, but untreated or severe disease can lead to:

• Airway obstruction – life‑threatening angioedema of the tongue or larynx.
• Chronic sleep loss and fatigue due to persistent itching.
• Psychological distress – anxiety, depression, or social isolation.
• Secondary skin infection from excessive scratching.
• In hereditary angioedema, repeated episodes can cause permanent tissue damage or laryngeal scarring.

When to Seek Emergency Care

References

• Mayo Clinic. “Urticaria (hives).” 2023. https://www.mayoclinic.org
• American Academy of Dermatology. “Urticaria.” 2022. https://www.aad.org
• European Academy of Allergy and Clinical Immunology (EAACI) et al. “Guideline for the Management of Chronic Urticaria.” 2021.
• Cleveland Clinic. “Chronic Hives (Urticaria) and Its Impact on Quality of Life.” 2021.
• Centers for Disease Control and Prevention (CDC). “Allergy and Asthma: Managing Food Allergies.” 2023.
• World Health Organization. “Hereditary Angioedema.” 2022.
• National Institutes of Health (NIH). “Omalizumab for Chronic Spontaneous Urticaria.” 2022.

```